Valuation: Alto Neuroscience, Inc.

Market Cap 1.09B 988M 913M 825M 1.56B 102B 1.61B 10.98B 4.35B 54.81B 4.08B 4B 174B P/E 2026 *
-10.7x
P/E 2027 * -10.1x
Enterprise Value 809M 735M 679M 613M 1.16B 75.96B 1.2B 8.17B 3.24B 40.76B 3.04B 2.97B 129B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.74%
Yield 2026 *
-
Yield 2027 * -
1 day-8.19%
1 week-2.45%
Current month+20.00%
1 month+23.61%
3 months-15.62%
6 months+18.02%
Current year+52.36%
1 week 26.94
Extreme 26.94
33.5
1 month 21.45
Extreme 21.45
33.5
Current year 13.91
Extreme 13.9121
37.48
1 year 12.51
Extreme 12.51
37.48
3 years 1.6
Extreme 1.6
37.48
5 years 1.6
Extreme 1.6
37.48
10 years 1.6
Extreme 1.6
37.48
Manager TitleAgeSince
Chief Executive Officer 50 25/03/2019
Director of Finance/CFO 38 01/11/2022
Chief Operating Officer 53 20/05/2024
Director TitleAgeSince
Chairman 50 25/03/2019
Director/Board Member 47 01/04/2022
Director/Board Member 67 18/10/2023
Date Insider Type Main position Quantity % Market Cap. Importance
02/10/26 Exercice

Chief Financial Officer

110,000 0.2803%
30/09/26 Exercice

Chief Financial Officer

72,168 0.1839%
27/05/26 Free

Director

26,000 0.0814%
Change 5-day change 1-year change 3-year change Capi.($)
-8.19%-2.45%+123.95% - 1.09B
-1.29%-3.91%+51.98%+69.06% 65.56B
-2.07%-0.56%+8.46%+90.01% 60.41B
-0.45%+0.97%+23.73%+88.00% 55.76B
-1.26%-1.45%+12.43%+117.42% 46.98B
-0.15%-5.06%+20.00%+29.27% 43.63B
-3.15%-16.63%+146.30%+685.27% 36.09B
+0.23%+2.14%+14.85%+46.22% 36.7B
-0.77%-2.12%+77.42%+58.10% 32.9B
+1.42%+5.84%-36.40%+402.78% 26.96B
Average -1.57%-1.72%+44.27%+176.24% 41B
Weighted average by Cap. -0.99%-1.58%+35.03%+150.29%

Financials

2026 *2027 *
Net sales - -
Net income -109M -98.95M -91.42M -82.58M -156M -10.23B -161M -1.1B -436M -5.49B -409M -400M -17.38B -130M -118M -109M -98.62M -186M -12.21B -193M -1.31B -520M -6.55B -488M -478M -20.76B
Net Debt -279M -253M -234M -211M -399M -26.18B -413M -2.81B -1.12B -14.05B -1.05B -1.02B -44.5B -365M -332M -306M -277M -522M -34.26B -540M -3.68B -1.46B -18.39B -1.37B -1.34B -58.24B
Projected Income Statement - Annual - Alto Neuroscience, Inc.
Logo Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
Employees
68
Date Price Change Volume
16/11/26 $27.12 -8.19% 789,244
13/11/26 $29.54 -3.53% 610,927
12/11/26 $30.62 -1.70% 1,288,571
11/11/26 $31.15 +8.88% 1,221,967
10/11/26 $28.61 +2.91% 515,840
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Alto Neuroscience, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
27.12USD
Average target price
38.67USD
Spread / Average Target
+42.58%
  1. Stock Market
  2. Stocks
  3. ANRO Stock